Transdermal Ibuprofen Avoids GI Bleeding
By Biotechdaily staff writers
Posted on 22 Dec 2004
A new transdermal version of ibuprofen is being developed that would eliminate the possibility of gastrointestinal (GI) bleeding, which can accompany use of ibuprofen taken internally.Posted on 22 Dec 2004
The new version is based on the transdermal-delivery platform developed by TransDermal Systems, a subsidiary of Strategic Science & Technologies (Wellesley, MA, USA). This platform forms an environment in the delivery vehicle that is biophysically hostile to ibuprofen, causing the ibuprofen to prefer to move from the vehicle into the tissue to which it is applied.
Healthcare professionals fear that increased use of ibuprofen by patients formerly taking COX-2 inhibitors may further increase the incidence of hospitalization and death from GI bleeding. Use of a transdermal ibuprofen could drastically reduce this possibility.
Another advantage of transdermal administration of drugs that act locally is that a much lower dose is needed. For example, if 400 mg of an oral anti-inflammatory drug was required to treat wrist pain systemically, the same relief could be achieved by applying only 0.5 mg of a transdermal version.
Related Links:
Strategic Science & Technologies
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Thyroid Test
Anti-Thyroid EIA Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
